With a phase III trial bearing an identical endpoint and dosing schedule already under way, Alnylam Pharmaceuticals Inc. reported favorable data from the phase II open-label extension (OLE) study with patisiran, the RNAi therapy for transthyretin (TTR)-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP).